Optimized production, purification, and radiolabeling of the ²⁰³Pb/²¹²Pb theranostic pair for nuclear medicine.

ABSTRACT: TRIUMF is one of the only laboratories in the world able to produce both lead-203 (²⁰³Pb, t_1/2 = 51.9 h) and ²¹²Pb (t_1/2 = 10.6 h) onsite via its 13 and 500 MeV cyclotrons, respectively. Together, ²⁰³Pb and ²¹²Pb form an element-equivalent theranostic pair that potentiate image-guided, personalized cancer treatment, using ²⁰³Pb as a single-photon emission computed tomography (SPECT) source, and ²¹²Pb for targeted alpha therapy. In this study, improvements to ²⁰³Pb production were accomplished by manufacturing electroplated, silver-backed thallium (Tl) targets to improve target thermal stability, which allow for higher currents during irradiation. We implemented a novel, two-column purificatio

SUBMITTER: McNeil BL 

PROVIDER: S-EPMC10313663 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature